

Pharmacy and Pharmacovigilance in Summary

Mr. Borse Sumit Jagdish, Dr. Tabrej Mujawar, Shaikh Miran Abdul Shafiq

Gangamai College of Pharmacy, Nagaon, Dhule, Maharashtra India

Abstract: *The field of pharmacy has advanced remarkably in recent years. There has been a change in trend from a focus on products to one on patients. Pharmacists who offer services that advance medication safety can expand their involvement in pharmacovigilance. Pharmacovigilance is defined by vigilare (to keep watch) and pharmakon (for medication). The science and practices around the gathering, identifying, and evaluation of adverse event data are known as pharmacovigilance. The complicated idea of pharmacovigilance pertains to medical devices as well as chemical, biological, and botanical medications. To find and stop any problems related to the suspected product, medical professionals and patients provide the primary data. Pharmacovigilance addresses paradoxical reactions, polypharmacy, severe adverse events, and negative pharmacological effects. PV also encompasses ineffective vaccinations, drug interactions, inappropriate use, overdose, poisoning, and pharmaceutical errors.*

Keywords: Drug safety, pharmacovigilance, PvPI, and ADRs

REFERENCES

- [1]. Parthasarathi G, Olsson S. Adverse drug reactions. A textbook of clinical pharmacy practice. Orient Longman, 2004; 8: 84-86.
- [2]. WHO Policy Perspectives on Medicines. Looking at the Pharmacovigilance: ensuring the safe use of medicines. Geneva: WHO, 2004.
- [3]. Effective communications in Pharmacovigilance. The Erice Report. International Conference on Developing Effective Communications in Pharmacovigilance, Erice Declaration, Erice, Sicily, 1997.
- [4]. Mann RD, Andrews EB. Pharmacovigilance, John Wiley and Sons Ltd., Chichester, 2002.
- [5]. Arifa SK et al., Pharmacovigilance: A Discourse Functional Perspective. American Journal of Pharm Tech Research, 2016. 238
- [6]. Apoorva B M, Kiran L J, Chetan Kumar S. Review of the softwares used in pharmacovigilance and clinical trials, October 27-29, 2014.
- [7]. Gunasakaran S, Satheesh K R. A Practical Guide on Pharmacovigilance for Beginners. First Edition.
- [8]. The Uppsala monitoring system, WHO collaborating Centre for International Drug Monitoring World Health Organization, 2002; 28-34.
- [9]. Avani Patel, D. Giles. Pharmacovigilance: A review. International Journal of Pharmaceutical & Biological Archives, 2011; 2(6): 1569-1574.
- [10]. WHO, Safety of medicines in public health programs: Pharmacovigilance an essential tool, WHO, 2006. Department of CDSCO, Ministry of Health and Family welfare, Government of India: Protocol for National pharmacovigilance program, November 2004.
- [11]. Danole AB et al., Pharmacovigilance: An Overview. American Journal of Pharm Tech Research, 2014.
- [12]. Ankur Rohilla, et al., Pharmacovigilance: Needs and Objectives Journal of Advanced Pharmacy Education & Research, Oct-Dec 2012; 2(4): 201.
- [13]. Livio F, Renard D, Buclin T. Pharmacovigilance. Rev Med Suisse, 2012; 8: 116-9.
- [14]. Hall M, McCormack P, Arthur N, Feely J. The spontaneous reporting of ADRs by nurses. Br J Clin Pharmacol, 1995; 40: 2270-2279.
- [15]. Prakash S. Pharmacovigilance in India, Indian J Pharmacol, 2007; 1: 125-128.
- [16]. Vijay Venkatraman Janarthanan et al., Pharmacist as Pharmacovigilance Practitioner. Indian Journal of Pharmacy Practice, Jan-Mar, 2015; 8(1).
- [17]. Routledge P. 150 years of pharmacovigilance. Lancet, 1998; 351: 1200-1.

- [18]. Commission on Anaesthetics. *Lancet*, 1893; i: 629-38.
- [19]. Woolf AD. The Haitian diethylene glycol poisoning tragedy: a dark wood revisited. *JAMA*, 1998; 279: 1215-6.
- [20]. FoodConsumerMagzine. <http://www.fda.gov/downloads/AboutFDA/WhatWeDo/History/Origin/ucm125604.doc> (1981). Accessed 22 Dec 2017.
- [21]. Manual for good Bioavailability and Bioequivalence Practices, Vol. 1, Mod. 1. Clinical Phase. 1st ed. Brazil; 2002. p.5-6. Available from: [Last accessed on 2010 Aug 25].
- [22]. Kulkarni RD. Reporting system for rare side effects of non-narcotic analgesics in India: Problems and opportunities. *Med Toxicol*, 1986; 1: 110-3.
- [23]. Jayesh Km Rajgopal, Kajal Shilpi, Shrivastav AK. *Innovare Journal of Medical Sciences*, 2016; 4(4).
- [24]. Effects(ADRs)", *International Journal of Computer Applications & Information Technology*, January 2013; II: 01-04.
- [25]. Shuka SS, Gidwani Bina, Pandey R, Rao SP, Singh V and Vyas Amber, "Importance of Pharmacovigilance in Indian Pharmaceutical Industry", *Asian Journal of Research in Pharmaceutical Science*, 2012; 2: 04-08.
- [26]. Stephen A Ward, Antimalarial drugs and pregnancy: Safety, Pharmacokinetics, Pharmacovigilance. *Lancet Infect Disease Vol 7*; 2007. Available from <http://infection.thelancet.com>.
- [27]. Norwood PK, Sampson AR, A Statistical methodology for post marketing surveillance of adverse drug reaction reports, *Stat Med*, 1988; 7: 1023-1030.
- [28]. Evans SJ, Use of proportional reporting ratios for signal generation from spontaneous adverse drug reaction reports, *Pharmacoepidemiol Drug Saf*, 2001; 10: 483-486.
- [29]. Bate A, Evans SJ, Quantitative signal detection using spontaneous ADR reporting, *Pharmacoepidemiol Drug Saf*, 2009; 1: 427-436.
- [30]. Hauben M, Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics, *Pharmacotherapy*, 2004; 2: 1122-1129.
- [31]. Lindquist M, from association to alert a revised approach to International Signal Analysis, *Pharmacopidemiol Drug Saf*, 1999; 8: 15-25.
- [32]. DuMouchel, Pregibon D, Empirical Bayes screening for multi item associations, *International Conference on Knowledge Discovery and Data Mining*, 2001; 3: 67-76.
- [33]. Pharmacovigilance programme in India; [cited on 5/08/2015]; Available from: URL: <http://www.ipc.gov.in/PvPI/pv-orginv.html>.
- [34]. AlhatBabita R. et al., *Pharmacovigilance: An overview* ISSN: 2231-2781 *IJRPC*, 2011; 1(4): 971-973.
- [35]. Wu WK, Pantalo N, Evaluation of outpatient adverse drug reactions leading to hospitalization, *Am J Health Syst Pharm*, 2003; 13: 253-259.
- [36]. Cosentio M, Leoni O, Banfi F, Lecchini S, Frigo G, Attitudes to adverse drug reaction reporting by medical practitioners in a northern Italian district, *pharmacol Res*, 1997; 2: 85-88.
- [37]. Sumit et al., *Pharmacovigilance in India: perspectives and prospects: journal of drug delivery & therapeutics*, 2013; 3(4): 237.
- [38]. Meslin EM. Protecting human subjects from harm through improved risk judgements. *IRB*, 1990; 12: 7-10.
- [39]. King NM, Churchill LR. Assessing and comparing potential benefits and risks of harm. *The oxford Textbook of Clinical Research Ethics*. In: Emanuel E, Grady C, Crouch RA, Lie RA, Miller FG, Wendler D Editors. New York: Oxford University Press, 2008; 514-526.
- [40]. Chapter 2- A Short History of Involvement in Drug Safety Monitoring by WHO "<http://apps.who.int/medicinedocs/en/d/Js4893e/3.html>) The importance of pharmacovigilance-safety monitoring of medicinal products who.int
- [41]. Jonas H, Philosophical reflections on experimenting with human subjects, *Daedalus*, 1969; 98: 219-247.
- [42]. Kalantri SP, Ethics in Clinical research, *Indian J Anaesth*, 2003; 47: 30-32.
- [43]. Indicator-Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessment in Developing Countries, USAID, December 2009: 1-10.

- [44]. Pranay Wal et al., Pharmacovigilance: Need for Indian Pharma Industry. International Research Journal Of Pharmacy, 2015; 6(11): ISSN 2230-8407.
- [45]. Nair MD. Pharmacovigilance: The need for a formal system in India. Available from: <http://www.pharmabiz.com>. [Last accessed on 2010 Aug 25].
- [46]. Kumar A. Past, present and future of pharmacovigilance in India. Syst Rev Pharm, 2011; 2: 55-8.
- [47]. Kumar S, Baldi A. Pharmacovigilance in India: Perspectives and Prospects. J drug Deliv Sci Technol, 2013; 3: 237-246.
- [48]. Ghewari P, Salunke S, Bhatiya N, Killedar S. Strategies and current scenario of pharmacovigilance in India. JADD, 2014; 1: 122-134.
- [49]. Ruhoy IS, Daughton CG. Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ Int., 2008; 34: 1157-1169.
- [50]. Rajanandh MG, Chamundeeswari D. Need of Pharmacovigilance in AYUSH drugs. Journal of pharmacovigilance, 2017; 5: ISSN 2329-6887.
- [51]. Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol, 2007; 39: 124-128.